title: Modified GTX as second-line therapy for advanced pancreatic adenocarcinoma.
abstract: BACKGROUND
  Advanced pancreatic cancer remains a lethal disease with no standard treatment beyond first-line palliative chemotherapy. Gemcitabine, docetaxel, and capecitabine (GTX) is a regimen that has come into use for advanced pancreatic cancer despite a paucity of randomized data.
  
  
  METHODS
  We have used a modified schedule of this regimen in the second-line setting aimed at biomodulating the activity of capecitabine by both docetaxel and gemcitabine. This report describes our experience with the use of modified GTX in nine patients with advanced pancreatic cancer as second-line chemotherapy.
  
  
  CONCLUSIONS
  In our series, the median overall survival was 8 months (range 5.2-10.8). Prospective studies of this regimen in the second-line setting are warranted.
authors.affiliation: Division of Hematology and Oncology, American University of Beirut Medical Center, Beirut, Lebanon, hma40@aub.edu.lb.
authors.forename: Hana
authors.initials: H
authors.lastname: Ajouz
authors.forename: Deborah
authors.initials: D
authors.lastname: Mukherji
authors.forename: Ali
authors.initials: A
authors.lastname: Haydar
authors.forename: Ahmad Sharif
authors.initials: AS
authors.lastname: Yakan
authors.forename: Ahmad
authors.initials: A
authors.lastname: Saleh
authors.forename: Elias
authors.initials: E
authors.lastname: Elias
authors.forename: Sally
authors.initials: S
authors.lastname: Temraz
authors.forename: Walid
authors.initials: W
authors.lastname: Faraj
authors.forename: Mohammad
authors.initials: M
authors.lastname: Khalife
authors.forename: Ali
authors.initials: A
authors.lastname: Shamseddine
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000069287:Capecitabine; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives; D000077143:Docetaxel; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000031:analogs & derivatives; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D010190:Pancreatic Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D011379:Prognosis; D012189:Retrospective Studies; D016879:Salvage Therapy; D015996:Survival Rate; D043823:Taxoids / Q000008:administration & dosage; D000093542:Gemcitabine
chemical_list: D043823:Taxoids; D003841:Deoxycytidine; D000077143:Docetaxel; D000069287:Capecitabine; D005472:Fluorouracil; D000093542:Gemcitabine